

## CORRECTION

[View Article Online](#)  
[View Journal](#) | [View Issue](#)CrossMark  
click for updatesCite this: *Med. Chem. Commun.*, 2015,  
6, 247DOI: 10.1039/c4md90044h  
[www.rsc.org/medchemcomm](http://www.rsc.org/medchemcomm)

## Correction: Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins

Jiang Wu,<sup>a</sup> Julia Shin,<sup>b</sup> Cara M. M. Williams,<sup>b</sup> Kieran F. Geoghegan,<sup>a</sup> Stephen W. Wright,<sup>c</sup> David C. Limburg,<sup>c</sup> Parag Sahasrabudhe,<sup>a</sup> Paul D. Bonin,<sup>e</sup> Bruce A. Lefker<sup>\*d</sup> and Simeon J. Ramsey<sup>b</sup>

Correction for 'Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins' by Jiang Wu *et al.*, *Med. Chem. Commun.*, 2014, 5, 1871–1878.

The following scheme captions were missing from the paper:

**Scheme 1** (a) 2-ethyl-4,4-dimethyl-4,5-dihydroxazole, NaHSO<sub>4</sub>, NMP, xylenes, 200 °C, 93%; (b) 10% Pd/C, acetic acid, 84%; (c) 2-methoxybenzenesulfonyl chloride, pyridine, 46%.

**Scheme 2** (a) acrylonitrile, NaOH, 26%; (b) Adam's catalyst, ethanol, CHCl<sub>3</sub>, 99%; (c) di-*tert*-butyl dicarbonate, TEA, THF, 37%; (d) 6, polymer bound TPP, DIAD, 79%; (e) benzyltrimethylammonium chloride, trichloroisocyanuric acid, H<sub>2</sub>O, ACN, 92%; (f) 5, pyridine, 68%; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0–20 °C, 100%; (h) desthiobiotin, DMF, DIEA, HATU, 15%.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>Structural Biology and Biophysics, Worldwide Medicinal Chemistry, Pfizer, Groton, CT 06340, USA

<sup>b</sup>Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA 02139, USA

<sup>c</sup>Worldwide Medicinal Chemistry, Pfizer, Groton, CT 06340, USA

<sup>d</sup>Worldwide Medicinal Chemistry, Pfizer, 610 Main Street, Cambridge, MA 02139, USA. E-mail: bruce.a.lefker@pfizer.com; Fax: +1 860-715-8059; Tel: +1 617-674-7450

<sup>e</sup>Primary Pharmacology Group, Pfizer, Groton, CT 06340, USA